Problems related to the large-scale production of a radiocontrast agent (iopamidol) and an MRI contrast agent (Prohance) are discussed. The specific nature of these problems is related to both the type of product and the associated processes required.These are in turn reflected in the requirements for the design and implementation of the manufacturing plants.